---
title: Biomarkers of Mortality and Morbidity in Children Hospitalized With Fever
nct_id: NCT04726826
overall_status: COMPLETED
sponsor: University of Alberta
study_type: OBSERVATIONAL
primary_condition: Fever
countries: Uganda
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04726826.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04726826"
ct_last_update_post_date: 2021-01-27
last_seen_at: "2026-05-12T07:33:03.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Biomarkers of Mortality and Morbidity in Children Hospitalized With Fever

**Official Title:** Predictive Biomarkers of Mortality and Morbidity in Children Hospitalized for Acute Febrile Illness

**NCT ID:** [NCT04726826](https://clinicaltrials.gov/study/NCT04726826)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 2500
- **Lead Sponsor:** University of Alberta
- **Collaborators:** University of Toronto, Global Health Uganda LTD
- **Conditions:** Fever
- **Start Date:** 2012-02-01
- **Completion Date:** 2013-09-15
- **CT.gov Last Update:** 2021-01-27

## Brief Summary

The objective of this study is to identify clinically informative biomarkers of host defense pathways with potential utility as diagnostic and prognostic tools among children hospitalized with acute febrile illness in a resource-constrained sub-Saharan African setting.

The working hypothesis is that a panel of biomarkers, readily measurable from a peripheral blood sample, may serve as a clinically useful instrument to distinguish between common pediatric causes of fever, predict those children at greatest need of aggressive supportive care and/or adjunctive therapies, and identify those children at greatest risk of mortality. The use of objective and quantitative tools may facilitate the triage and clinical care of febrile children admitted to hospital in the sub-Saharan African context.

## Detailed Description

For pediatric patients presenting to Jinja Regional Referral Hospital in whom admission to hospital is deemed necessary by an attending physician, the parent or guardian will be approached for consent to participate in the study. If granted, a small volume (1mL) of blood will be withdrawn for processing and storage. A RDT for malaria and whole blood lactate level will be performed at the bedside. Basic demographic and clinical data will be collected from the case admission record, and patients will be followed during their hospital admission. Possible outcomes will include: death, discharge without disability, discharge with disability, abscondment, and loss to follow-up. The length of stay among survivors will be recorded (excluding patients leaving against medical advice).

Serum samples will be shipped to the collaborating laboratory in Canada for analysis for biomarkers. ELISA-based commercially-available assays for biomarker levels will be used to quantify biomarker levels. In order to measure levels of 13 biomarkers from a plasma sample of 500uL or less, highly co-ordinated procedures with experienced technicians are required to perform the ELISA. Our laboratory in Canada has established protocols, experienced staff able to perform the testing, as well as equipment and reagents allowing the testing to be done efficiently. While it would be desirable to augment Ugandan capacity for biomarker testing, this would require significant investment of time and resources for training and testing, and may not be feasible in the context of this early study. If biomarkers can be identified that have clinical utility, laboratory capacity for ELISA measurement of levels should be developed or a simplified platform (e.g., lateral flow immunochromatographic test) should be developed.

Pneumonia and meningitis will be diagnosed clinically. A combination of tachypnea, respiratory distress (nasal flaring, intercostal and/or subcostal indrawing, or cyanosis) and characteristic findings on chest auscultation (asymmetrical air entry, crackles, dullness to percussion) will be used to make a clinical diagnosis of pneumonia. In our setting, chest x-ray is not available on site and radiographic confirmation will not be routinely available. Neck stiffness, positive Kernig's or Brudzinsky's signs, convulsions and coma will be used to make a diagnosis of meningitis. Where a lumbar puncture is performed, according to clinical judgment, the results will be used to complement clinical diagnosis. CSF pleiocytosis or a positive CSF culture for recognized pathogens will be used to support the diagnosis of meningitis.

## Eligibility

- **Minimum age:** 2 Months
- **Maximum age:** 5 Years
- **Sex:** ALL

```
Inclusion Criteria:

1. Age 2 months to 5 years
2. History of fever within past 48 hours or axillary temperature \>37.5°C
3. Hospital admission warranted based on clinician judgment
4. Consent to blood sampling and data collection

Exclusion Criteria:

1. Outside eligible age range
2. No history or objective evidence of fever
3. Diarrheal illness without other symptoms
4. Outpatient management
5. Denial of consent to participate in study
```

## Interventions

- **Diagnostic and prognostic biomarkers** (DIAGNOSTIC_TEST) — Observational study of biomarkers predictive of morbidity and mortality in febrile children

## Primary Outcomes

- **Mortality** _(time frame: through study completion, an average of 1 week)_ — in-hospital mortality

## Secondary Outcomes

- **Hospital length of stay** _(time frame: through study completion, an average of 1 week)_
- **Lambarene organ dysfunction score (LODS), a composite clinical severity score** _(time frame: evaluated at admission)_
- **Signs of Inflammation in Children that Kill (SICK), a composite clinical severity score** _(time frame: evaluated at admission)_

## Locations (1)

- Jinja Regional Referral Hospital, Jinja, Uganda

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.jinja regional referral hospital|jinja||uganda` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04726826.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04726826*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*